Search research articles
Contact Us
Filters
Showing results (21-30 of 330) with videos related to
Page
of 33
Sort By:
The Oncologist
|
August 4, 2016
Ionophore Antibiotics as Cancer Stem Cell-Selective Drugs: Open Questions
Maximilian Boesch, Sieghart Sopper, Dominik Wolf
The New England Journal of Medicine
|
February 10, 2021
Atezolizumab for PD-L1-Selected Patients with NSCLC
Andreas Pircher, Isabel Heidegger, Dominik Wolf
Oncoimmunology
|
May 7, 2014
Implementing combinatorial immunotherapeutic regimens against cancer: The concept of immunological conditioning
Dominik Wolf, Annkristin Heine, Peter Brossart
The Journal of Clinical Investigation
|
March 1, 2024
The multivisceral landscape of colorectal cancer metastasis: implications for targeted therapies
Dominik Wolf, Stefan Salcher, Andreas Pircher
Oncoscience
|
October 2, 2015
NK cell modulation by JAK inhibition
Kathrin Schönberg, Janna Rudolph, Dominik Wolf
Molecular Therapy. Oncology
|
April 20, 2026
NR2F6-modified CAR T cells drive extrinsic immunogenic cell death and antigen-agnostic immunity in solid tumors
Victoria Klepsch, Dominik Wolf, Gottfried Baier
Leukemia & Lymphoma
|
April 10, 2008
Possible role for gene expression profiling in predicting responses to conventional or targeted drugs in patients with chronic myeloid leukemia
Stefan Schmidt, Guenther Gastl, Dominik Wolf
Blood
|
November 30, 2013
Ruxolitinib is a potent immunosuppressive compound: is it time for anti-infective prophylaxis?
Annkristin Heine, Peter Brossart, Dominik Wolf
Stem Cells International
|
January 23, 2016
Optimized Stem Cell Detection Using the DyeCycle-Triggered Side Population Phenotype
Maximilian Boesch, Dominik Wolf, Sieghart Sopper
The New England Journal of Medicine
|
March 26, 2015
More on remission of recalcitrant dermatomyositis treated with ruxolitinib
Thorsten Hornung, Dominik Wolf, Joerg Wenzel
Page
of 33
Search research articles
Search
Showing results (21-30 of 330) with videos related to
Sort By:
Page
of 33
The Oncologist
|
August 4, 2016
Ionophore Antibiotics as Cancer Stem Cell-Selective Drugs: Open Questions
Maximilian Boesch, Sieghart Sopper, Dominik Wolf
The New England Journal of Medicine
|
February 10, 2021
Atezolizumab for PD-L1-Selected Patients with NSCLC
Andreas Pircher, Isabel Heidegger, Dominik Wolf
Oncoimmunology
|
May 7, 2014
Implementing combinatorial immunotherapeutic regimens against cancer: The concept of immunological conditioning
Dominik Wolf, Annkristin Heine, Peter Brossart
The Journal of Clinical Investigation
|
March 1, 2024
The multivisceral landscape of colorectal cancer metastasis: implications for targeted therapies
Dominik Wolf, Stefan Salcher, Andreas Pircher
Oncoscience
|
October 2, 2015
NK cell modulation by JAK inhibition
Kathrin Schönberg, Janna Rudolph, Dominik Wolf
Molecular Therapy. Oncology
|
April 20, 2026
NR2F6-modified CAR T cells drive extrinsic immunogenic cell death and antigen-agnostic immunity in solid tumors
Victoria Klepsch, Dominik Wolf, Gottfried Baier
Leukemia & Lymphoma
|
April 10, 2008
Possible role for gene expression profiling in predicting responses to conventional or targeted drugs in patients with chronic myeloid leukemia
Stefan Schmidt, Guenther Gastl, Dominik Wolf
Blood
|
November 30, 2013
Ruxolitinib is a potent immunosuppressive compound: is it time for anti-infective prophylaxis?
Annkristin Heine, Peter Brossart, Dominik Wolf
Stem Cells International
|
January 23, 2016
Optimized Stem Cell Detection Using the DyeCycle-Triggered Side Population Phenotype
Maximilian Boesch, Dominik Wolf, Sieghart Sopper
The New England Journal of Medicine
|
March 26, 2015
More on remission of recalcitrant dermatomyositis treated with ruxolitinib
Thorsten Hornung, Dominik Wolf, Joerg Wenzel
Page
of 33